|
|
|
|
|
Legal status
Patent lapsed (non-payment of fees)
| (51) | INT.CL. | C07D 417/12 | (2006.01) |
| A61P 35/00 | (2006.01) | ||
| A61K 31/4439 | (2006.01) |
| (11) | Number of the document | 3837256 |
| (13) | Kind of document | T |
| (96) | European patent application number | 19779145.2 |
| Date of filing the European patent application | 2019-08-12 | |
| (97) | Date of publication of the European application | 2021-06-23 |
| (45) | Date of publication and mention of the grant of the patent | 2023-03-08 |
| (46) | Date of publication of the claims translation | 2023-06-12 |
| (86) | Number | PCT/IB2019/056847 |
| Date | 2019-08-12 |
| (87) | Number | WO 2020/035779 |
| Date | 2020-02-20 |
| (30) | Number | Date | Country code |
| 201862765138 P | 2018-08-17 | US |
| (72) |
ADAIR, Christopher , US
PAPILLON, Julien , US
NAKAJIMA, Katsumasa , US
SMITH, Troy Douglas , US
NTAGANDA, Rukundo , US
|
| (73) |
Novartis AG ,
Lichtstrasse 35, 4056 Basel,
CH
|
| (74) |
Jurga PETNIŪNAITĖ,
AAA Law, A. Goštauto g. 40B, Verslo centras "Dvyniai", LT-03163 Vilnius,
LT
|
| (54) | Karbamido junginiai ir kompozicijos kaip SMARCA2 / BRM atfazės inhibitoriai |
| UREA COMPOUNDS AND COMPOSITIONS AS SMARCA2/BRM-ATPASE INHIBITORS |
| Payment date | Validity (years) | Amount | |
| 2024-07-18 | 6 | 139.00 EUR |
| Patent lapsed (non-payment of fees) | ||
| Invalidation date | 2025-08-12 |